CEL-SCI Co. (NYSEAMERICAN:CVM) insider Eyal Talor sold 8,192 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $2.06, for a total transaction of $16,875.52. Following the completion of the transaction, the insider now directly owns 117,698 shares of the company’s stock, valued at approximately $242,457.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Eyal Talor also recently made the following trade(s):
- On Friday, January 12th, Eyal Talor sold 101 shares of CEL-SCI stock. The stock was sold at an average price of $2.15, for a total transaction of $217.15.
- On Tuesday, January 16th, Eyal Talor sold 1,808 shares of CEL-SCI stock. The stock was sold at an average price of $2.15, for a total transaction of $3,887.20.
CEL-SCI Co. (CVM) traded up $0.24 during midday trading on Monday, hitting $2.20. 263,247 shares of the company’s stock were exchanged, compared to its average volume of 294,350. The stock has a market capitalization of $23.19, a PE ratio of -1.36 and a beta of -1.60. CEL-SCI Co. has a fifty-two week low of $1.46 and a fifty-two week high of $4.00.
Separately, Dawson James reaffirmed a “neutral” rating on shares of CEL-SCI in a report on Monday, October 16th.
ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2018/01/22/cel-sci-co-cvm-insider-sells-16875-52-in-stock.html.
CEL-SCI Company Profile
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.